Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data

ACT-1004-1239 is a potent, selective, first-in-class CXCR7 antagonist, which shows a favorable preclinical and clinical profile. Here we report the metabolites and the metabolic pathways of ACT-1004-1239 identified using results from in vitro and in vivo studies. Two complementary in vitro studies (...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Christine, Seeland, Swen, Segrestaa, Jerome, Gnerre, Carmela, Hogeback, Jens, Meyer zu Schwabedissen, Henriette E., Dingemanse, Jasper, Sidharta, Patricia N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006992/
https://www.ncbi.nlm.nih.gov/pubmed/35431953
http://dx.doi.org/10.3389/fphar.2022.812065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006992/
https://www.ncbi.nlm.nih.gov/pubmed/35431953
http://dx.doi.org/10.3389/fphar.2022.812065

Ejemplares similares